{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rezaei A"],"funding":["European Research Council","Deutsche Forschungsgemeinschaft (German Research Foundation)","EC | EU Framework Programme for Research and Innovation H2020 | H2020 European Institute of Innovation and Technology (H2020 The European Institute of Innovation and Technology)","EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)"],"pagination":["3442"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11992041"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Clinical and genetic research links altered cholesterol metabolism with ALS development and progression, yet pinpointing specific pathomechanisms remain challenging. We investigated how cholesterol dysmetabolism interacts with protein aggregation, demyelination, and neuronal loss in ALS. Bulk RNAseq transcriptomics showed decreased cholesterol biosynthesis and increased cholesterol export in ALS mouse models (GA-Nes, GA-Camk2a GA-CFP, rNLS8) and patient samples (spinal cord), suggesting an adaptive response to cholesterol overload. Consequently, we assessed the efficacy of the cholesterol-binding drug 2-hydroxypropyl-β-cyclodextrin (CD) in a fast-progressing C9orf72 ALS mouse model with extensive poly-GA expression and myelination deficits. CD treatment normalized cholesteryl ester levels,"],"journal":["Nature communications"],"pubmed_title":["Correction of dysregulated lipid metabolism normalizes gene expression in oligodendrocytes and prolongs lifespan in female poly-GA C9orf72 mice."],"pmcid":["PMC11992041"],"funding_grant_id":["390857198","407495230","423957469","101057649","101117710"],"pubmed_authors":["LaClair KD","Janjic A","Franzenburg S","Liebscher S","Isilgan HB","Knogler J","Farny D","Rezaei A","Hagan N","Bauernschmitt F","Gokce O","Zeng Q","Gunes ZI","Kislinger G","Parisi LR","Zhou Q","Dhingra A","Nuscher B","Arzberger T","Yang C","Enard W","Gouna G","Ofengeim D","Kocsis-Jutka V","Koppenbrink J","Simons M","Kaya T","Edbauer D","Beltran E","Katona E"],"additional_accession":[]},"is_claimable":false,"name":"Correction of dysregulated lipid metabolism normalizes gene expression in oligodendrocytes and prolongs lifespan in female poly-GA C9orf72 mice.","description":"Clinical and genetic research links altered cholesterol metabolism with ALS development and progression, yet pinpointing specific pathomechanisms remain challenging. We investigated how cholesterol dysmetabolism interacts with protein aggregation, demyelination, and neuronal loss in ALS. Bulk RNAseq transcriptomics showed decreased cholesterol biosynthesis and increased cholesterol export in ALS mouse models (GA-Nes, GA-Camk2a GA-CFP, rNLS8) and patient samples (spinal cord), suggesting an adaptive response to cholesterol overload. Consequently, we assessed the efficacy of the cholesterol-binding drug 2-hydroxypropyl-β-cyclodextrin (CD) in a fast-progressing C9orf72 ALS mouse model with extensive poly-GA expression and myelination deficits. CD treatment normalized cholesteryl ester levels,","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-03T01:19:39.794Z","creation":"2025-07-13T03:04:59.558Z"},"accession":"S-EPMC11992041","cross_references":{"pubmed":["40216746"],"doi":["10.1038/s41467-025-58634-4"]}}